208 related articles for article (PubMed ID: 28474504)
1. Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells.
Gaignage M; Marillier RG; Uyttenhove C; Dauguet N; Saxena A; Ryffel B; Michiels T; Coutelier JP; Van Snick J
Immun Inflamm Dis; 2017 Jun; 5(2):200-213. PubMed ID: 28474504
[TBL] [Abstract][Full Text] [Related]
2. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.
Zhang Y; Shlomchik WD; Joe G; Louboutin JP; Zhu J; Rivera A; Giannola D; Emerson SG
J Immunol; 2002 Dec; 169(12):7111-8. PubMed ID: 12471148
[TBL] [Abstract][Full Text] [Related]
3. The TLR7 ligand R848 prevents mouse graft-
Gaignage M; Marillier RG; Cochez PM; Dumoutier L; Uyttenhove C; Coutelier JP; Van Snick J
Haematologica; 2019 Feb; 104(2):392-402. PubMed ID: 30213828
[TBL] [Abstract][Full Text] [Related]
4. TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms.
Brown GR; Lee EL; Thiele DL
J Immunol; 2003 May; 170(10):5082-8. PubMed ID: 12734353
[TBL] [Abstract][Full Text] [Related]
5. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
6. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.
Asavaroengchai W; Wang H; Wang S; Wang L; Bronson R; Sykes M; Yang YG
Biol Blood Marrow Transplant; 2007 Jan; 13(1):46-55. PubMed ID: 17222752
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
8. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
9. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
11. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
[TBL] [Abstract][Full Text] [Related]
12. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
13. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Weber M; Rudolph B; Stein P; Yogev N; Bosmann M; Schild H; Radsak MP
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1696-704. PubMed ID: 25132527
[TBL] [Abstract][Full Text] [Related]
14. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.
Yang YG; Dey BR; Sergio JJ; Pearson DA; Sykes M
J Clin Invest; 1998 Dec; 102(12):2126-35. PubMed ID: 9854048
[TBL] [Abstract][Full Text] [Related]
15. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease.
Weber M; Stein P; Prüfer S; Rudolph B; Kreft A; Schmitt E; Bopp T; Roers A; Schild H; Fillatreau S; Radsak MP
Eur J Immunol; 2014 Jun; 44(6):1857-65. PubMed ID: 24643745
[TBL] [Abstract][Full Text] [Related]
16. Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4(+) T Cells after Allogeneic Stem Cell Transplantation.
Gauthier SD; Leboeuf D; Manuguerra-Gagné R; Gaboury L; Guimond M
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1721-31. PubMed ID: 26151303
[TBL] [Abstract][Full Text] [Related]
17. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.
Wang H; Asavaroengchai W; Yeap BY; Wang MG; Wang S; Sykes M; Yang YG
Blood; 2009 Apr; 113(15):3612-9. PubMed ID: 19211507
[TBL] [Abstract][Full Text] [Related]
19. Suppression of lentivirus-mediated transgenic dendritic cells in graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Xu YJ; Chen WR; Li DP; Song LX; Wu JQ; Zhang P; Li ZY; Huang YH
Genet Mol Res; 2015 Sep; 14(3):11444-55. PubMed ID: 26436385
[TBL] [Abstract][Full Text] [Related]
20. Regulatory role of host CD8+ T lymphocytes in experimental graft-versus-host disease across a single major histocompatibility complex class II incompatibility.
de Lavareille A; Prigogine C; Paulart F; Nagy N; Habran C; Haddou NO; Le Moine A; Salmon I; Goldman M; Flamand V
Transplantation; 2005 Nov; 80(9):1293-9. PubMed ID: 16314798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
